Mylan launches generic Paraplatin Injection in USA

9 June 2014

US generics major Mylan (Nasdaq: MYL) has launched carboplatin injection, 50mg/5ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's (NYSE: BMY) Paraplatin injection, in the USA.

Mylan received final approval from the Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. Mylan also received final approval for carboplatin injection, 150mg/15ml, 450mg/45ml, 600mg/60ml, in multi-dose vials, and intends to launch these presentations subsequently.

Carboplatin injection, in the named dosages, had US sales of around $30.4 million for the 12 months ending March 31, 2014, according to IMS Health quoted by Mylan. This launch bolsters Mylan's growing portfolio of cancer treatment and supportive care products, the company said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK